Taffic Tablets contain a fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide, three antiretroviral medicines that work together to treat HIV-1 infection. HIV attacks the immune system by targeting CD4 cells, which are essential for fighting infections. Taffic helps control the virus and protects the immune system from further damage.

Bictegravir is an integrase strand transfer inhibitor (INSTI). It blocks the HIV integrase enzyme, which the virus needs to insert its genetic material into human cells. By stopping this step, bictegravir prevents HIV from multiplying. Emtricitabine and tenofovir alafenamide are nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). They interfere with the reverse transcriptase enzyme, which HIV uses to make copies of itself. This further reduces viral replication.

When taken regularly as prescribed, Taffic lowers the amount of HIV in the blood (viral load) to very low or undetectable levels. This helps improve immune function, reduce HIV- and AIDS-related symptoms, and lower the risk of transmitting the virus to others. Taffic does not cure HIV or AIDS, but it is an effective long-term treatment that allows many people living with HIV to lead healthier, more active lives. Regular medical follow-up is essential during treatment.